aiqbench analysis
SciSparc's subsidiary, NeuroThera Labs, has completed internal validation of a hybrid workflow that maps clinical trial datasets onto energy landscapes for Quantum Markov Chain Monte Carlo analysis. This technical milestone demonstrates the practical utility of quantum-classical architectures in handling continuous probability distributions essential for complex biomedical analytics. The achievement marks progress toward leveraging emerging quantum hardware to solve specific computational bottlenecks in drug development rather than offering general-purpose speedups.
SciSparc Ltd : SciSparc : Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S & P 500 company
TEL AVIV, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, has successfully completed internal validation of a proprietary quantum sampling workflow developed platform for clinical trials data analysis (the "Platform"). The validated workflow enables continuous probability distributions to be represented and analyzed within a quantum computing framework. The implementation was developed and evaluated using an…
Excerpt shown under the publisher's RSS terms · 84 words · full text and figures are on the publisher's site
